Ceftizone 500 mg/vial (IV Injection)

500 mg vial: ৳ 140.53

Medicine Details

Indications

  • Lower respiratory tract infections
  • Acute Bacterial Otitis Media
  • Skin and skin structure infections
  • Urinary tract infections
  • Gonorrhea
  • Bacterial Septicemia
  • Bone and joint infections
  • Meningitis
  • Prevention of postoperative infections
  • Perioperative prophylaxis of infections associated with surgery

Mode of Action

Ceftizone is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic. It has potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. Like other cephalosporins and penicillins, Ceftizone kills bacteria by interfering with the synthesis of the bacterial cell wall. Ceftizone has a high degree of stability in the presence of beta lactamases. A remarkable feature of Ceftizone is its relatively long plasma elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most patients. Ceftizone is not metabolized in the body. About 40-65% of a dose of Ceftizone is excreted unchanged in the urine; the remainder is excreted in the bile and ultimately found in the feces as unchanged drug and microbiologically inactive compound. The drug is highly protein bound (95%).

Dosage

  • 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day)
  • 1 to 2 g IV or IM once a day (or in equally divided doses twice a day) for Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections, Meningitis. Maximum dose: 4 gm/day
  • 250 mg IM as a single dose for Uncomplicated gonococcal infections
  • 1 g IV as a single dose 30 to 120 minutes before surgery for Surgical prophylaxis
  • 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day) for Infants and Children (01 month or older). Maximum dose: 2 gm/day

Administration

  • For Intramuscular Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in 2 ml Lidocaine HCI 1% injection or 1 g Ceftriaxone in 3.5 ml of Lidocaine HCI 1% injection
  • For Intravenous Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in 5 ml of Water for injection or 1 g Ceftriaxone in 10 ml of Water for injection USP or 2 g Ceftriaxone in 20 ml of Water for injection
  • The injection should be administered over 2-4 minutes, by Intramuscular or Intravenous injection or by tubing infusion over a period of 30 minutes at concentration between 10 mg/mL and 40 mg/mL. Before starting treatment through Ceftriaxone injection, patient tolerance test should be checked by administration of a test dose. (The use of freshly reconstituted solution is recommended. However, it maintains potency for at least 6 hours at room temperature or 24 hours at 5°C)

Interaction

No drug interactions have been reported.

Contraindications

Ceftizone should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.

Side Effects

  • Diarrhea
  • Nausea
  • Vomiting
  • Stomatitis
  • Glossitis
  • Rash
  • Pruritus
  • Urticaria
  • Edema
  • Erythema multiforme
  • Eosinophilia
  • Thrombocytopenia
  • Leucopenia
  • Anemia
  • Neutropenia
  • Elevations of SGOT or SGPT
  • Bilirubinemia
  • Nervousness
  • Confusion
  • Sleep disturbances
  • Headache
  • Hyperactivity
  • Convulsion
  • Hypertonia
  • Dizziness
  • Local phlebitis rarely following intravenous administration

Pregnancy & Lactation

Its safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Low concentrations of Ceftizone are excreted in human milk. Caution should be exercised when Ceftizone is administered to a lactating mother.

Precautions & Warnings

As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken. Anaphylactic shock requires immediate countermeasures such as intravenous epinephrine followed by a glucocorticoid. In rare cases, shadows suggesting sludge have been detected by sonograms of the gallbladder. This condition was reversible on discontinuation or completion of Ceftizone therapy. Even if such findings are associated with pain, conservative, nonsurgical management is recommended. During prolonged treatment the blood picture should be checked at regular intervals.

Use in Special Populations

Ceftizone must not be given to neonates if the neonate is premature and newborn (up to 28 days of age).

Overdose Effects

There is no specific antidote. Treatment of overdosage should be symptomatic.

Therapeutic Class

Third generation Cephalosporins

Storage Conditions

Vial store in a cool, dry place (below 30°C), away from light & moisture. Keep out of the reach of children.

Related Brands